Floatz logo

Benralizumab

Solid Carcinoma

Memorial Sloan Kettering Cancer Centermonoclonal_antibodyPhase 2Dormant
C
35/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
20/ 100
Competitive Position
81/ 100

Competitive context

45 Active assets in the Solid Carcinoma cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
National Cancer Institute (NCI)
Phase 1/2B
Palbociclib
Academic and Community Cancer Research United
Phase 2B
TIPIRACIL
Academic and Community Cancer Research United
Phase 2B
Trifluridine
Academic and Community Cancer Research United
Phase 2B
Binimetinib
Academic and Community Cancer Research United
Phase 2B

View all 50 →

Same molecule, other indications

Benralizumab is also rated in:

bullous pemphigoidDormant
C
Indicative ·
37 / 100
View asset →
bronchiectasisDormant
C
Indicative ·
37 / 100
View asset →
neoplasmDormant
C
Indicative ·
35 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →